Ignite Creation Date:
2025-12-25 @ 3:28 AM
Ignite Modification Date:
2026-02-25 @ 5:50 PM
Study NCT ID:
NCT02268305
Status:
COMPLETED
Last Update Posted:
2024-04-05
First Post:
2014-10-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
The Use of Methylsulfonylmethane (MSM) in the Treatment of Low Back Pain
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D017116', 'term': 'Low Back Pain'}], 'ancestors': [{'id': 'D001416', 'term': 'Back Pain'}, {'id': 'D010146', 'term': 'Pain'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C025910', 'term': 'dimethyl sulfone'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'amanda.j.crawford.ctr@health.mil', 'phone': '7026533583', 'title': 'Amanda Crawford', 'organization': 'MOMH'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': '16 weeks', 'eventGroups': [{'id': 'EG000', 'title': 'MSM 1000mg Twice a Day (6000 Mgs)', 'description': 'Group 1 will take by mouth three 1000 mg capsules twice a day (6000 mgs) of MSM plus standard of care naproxen\n\nMSM 1000mg twice a day (6000 mgs): MSM is believed to have anti-inflammatory properties. MSM is a largely tasteless, odorless, white, crystalline solid which is water soluble. It occurs naturally in the environment and is synthesized in the human body as a byproduct of dietary DMSO.', 'otherNumAtRisk': 50, 'deathsNumAtRisk': 50, 'otherNumAffected': 2, 'seriousNumAtRisk': 50, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Placebo Capsules Twice a Day', 'description': 'Group 2 will take by mouth three placebo capsules twice a day plus standard of care naproxen\n\nPlacebo capsules twice a day: Placebo is a capsule filled with rice flour.', 'otherNumAtRisk': 50, 'deathsNumAtRisk': 50, 'otherNumAffected': 2, 'seriousNumAtRisk': 50, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'colitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 50, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 50, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'musculoskeletal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 50, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 50, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Pain Level', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '40', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MSM 1000mg Twice a Day (6000 Mgs)', 'description': 'Group 1 will take by mouth three 1000 mg capsules twice a day (6000 mgs) of MSM plus standard of care naproxen\n\nMSM 1000mg twice a day (6000 mgs): MSM is believed to have anti-inflammatory properties. MSM is a largely tasteless, odorless, white, crystalline solid which is water soluble. It occurs naturally in the environment and is synthesized in the human body as a byproduct of dietary DMSO.'}, {'id': 'OG001', 'title': 'Placebo Capsules Twice a Day', 'description': 'Group 2 will take by mouth three placebo capsules twice a day plus standard of care naproxen\n\nPlacebo capsules twice a day: Placebo is a capsule filled with rice flour.'}], 'classes': [{'title': 'Visual Analogue Scale Week 0', 'categories': [{'measurements': [{'value': '3.4', 'spread': '1.5', 'groupId': 'OG000'}, {'value': '3.7', 'spread': '2.0', 'groupId': 'OG001'}]}]}, {'title': 'Visual Analogue Scale Week 4', 'categories': [{'measurements': [{'value': '2.8', 'spread': '1.5', 'groupId': 'OG000'}, {'value': '2.9', 'spread': '2.5', 'groupId': 'OG001'}]}]}, {'title': 'Visual Analogue Scale Week 8', 'categories': [{'measurements': [{'value': '3.0', 'spread': '1.6', 'groupId': 'OG000'}, {'value': '3.1', 'spread': '2.4', 'groupId': 'OG001'}]}]}, {'title': 'Visual Analogue Scale Week 12', 'categories': [{'measurements': [{'value': '2.7', 'spread': '1.4', 'groupId': 'OG000'}, {'value': '3.2', 'spread': '2.4', 'groupId': 'OG001'}]}]}, {'title': 'Visual Analogue Scale Week 16', 'categories': [{'measurements': [{'value': '3.0', 'spread': '1.7', 'groupId': 'OG000'}, {'value': '3.4', 'spread': '2.4', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '16 weeks (Weeks 0, 4, 8, 12, and 16)', 'description': 'decrease in pain via analogue pain scale of 0-10 (with 10 being the worst pain)', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Roland-Morris Disability Questionnaire', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '40', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MSM 1000mg Twice a Day (6000 Mgs)', 'description': 'Group 1 will take by mouth three 1000 mg capsules twice a day (6000 mgs) of MSM plus standard of care naproxen\n\nMSM 1000mg twice a day (6000 mgs): MSM is believed to have anti-inflammatory properties. MSM is a largely tasteless, odorless, white, crystalline solid which is water soluble. It occurs naturally in the environment and is synthesized in the human body as a byproduct of dietary DMSO.'}, {'id': 'OG001', 'title': 'Placebo Capsules Twice a Day', 'description': 'Group 2 will take by mouth three placebo capsules twice a day plus standard of care naproxen\n\nPlacebo capsules twice a day: Placebo is a capsule filled with rice flour.'}], 'classes': [{'title': 'Roland Morris Disability Questionnaire Week 0', 'categories': [{'measurements': [{'value': '8.0', 'spread': '4.2', 'groupId': 'OG000'}, {'value': '8.4', 'spread': '5.1', 'groupId': 'OG001'}]}]}, {'title': 'Roland Morris Disability Questionnaire Week 4', 'categories': [{'measurements': [{'value': '5.8', 'spread': '4.3', 'groupId': 'OG000'}, {'value': '6.9', 'spread': '5.8', 'groupId': 'OG001'}]}]}, {'title': 'Roland Morris Disability Questionnaire Week 8', 'categories': [{'measurements': [{'value': '5.5', 'spread': '3.9', 'groupId': 'OG000'}, {'value': '6.7', 'spread': '5.5', 'groupId': 'OG001'}]}]}, {'title': 'Roland Morris Disability Questionnaire Week 12', 'categories': [{'measurements': [{'value': '5.4', 'spread': '4.2', 'groupId': 'OG000'}, {'value': '6.9', 'spread': '4.2', 'groupId': 'OG001'}]}]}, {'title': 'Roland Morris Disability Questionnaire Week 16', 'categories': [{'measurements': [{'value': '5.9', 'spread': '4.4', 'groupId': 'OG000'}, {'value': '6.8', 'spread': '5.7', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '16 weeks (Weeks 0, 4, 8, 12, and 16)', 'description': 'symptoms of lower back pain. 0 (no disability) to 24 (max. disability).', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Pain Impact Questionnaire-6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '40', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'MSM 1000mg Twice a Day (6000 Mgs)', 'description': 'Group 1 will take by mouth three 1000 mg capsules twice a day (6000 mgs) of MSM plus standard of care naproxen\n\nMSM 1000mg twice a day (6000 mgs): MSM is believed to have anti-inflammatory properties. MSM is a largely tasteless, odorless, white, crystalline solid which is water soluble. It occurs naturally in the environment and is synthesized in the human body as a byproduct of dietary DMSO.'}, {'id': 'OG001', 'title': 'Placebo Capsules Twice a Day', 'description': 'Group 2 will take by mouth three placebo capsules twice a day plus standard of care naproxen\n\nPlacebo capsules twice a day: Placebo is a capsule filled with rice flour.'}], 'classes': [{'title': 'Pain Impact Questionnaire Week 0', 'categories': [{'measurements': [{'value': '60.8', 'spread': '5.0', 'groupId': 'OG000'}, {'value': '60.2', 'spread': '6.9', 'groupId': 'OG001'}]}]}, {'title': 'Pain Impact Questionnaire Week 4', 'categories': [{'measurements': [{'value': '56.4', 'spread': '6.5', 'groupId': 'OG000'}, {'value': '56.7', 'spread': '8.5', 'groupId': 'OG001'}]}]}, {'title': 'Pain Impact Questionnaire Week 8', 'categories': [{'measurements': [{'value': '56.0', 'spread': '6.4', 'groupId': 'OG000'}, {'value': '57.2', 'spread': '9.6', 'groupId': 'OG001'}]}]}, {'title': 'Pain Impact Questionnaire Week 12', 'categories': [{'measurements': [{'value': '56.5', 'spread': '6.4', 'groupId': 'OG000'}, {'value': '56.3', 'spread': '9.3', 'groupId': 'OG001'}]}]}, {'title': 'Pain Impact Questionnaire Week 16', 'categories': [{'measurements': [{'value': '57.0', 'spread': '6.9', 'groupId': 'OG000'}, {'value': '57.8', 'spread': '8.6', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '16 weeks (Weeks 0, 4, 8, 12, and 16)', 'description': "6-item questionnaire measuring pain's interference with life activities. The total possible score of the PIQ-6 ranges from 40-78 points, where lower scores indicate less pain interference.", 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'MSM 1000mg Twice a Day (6000 Mgs)', 'description': 'Group 1 will take by mouth three 1000 mg capsules twice a day (6000 mgs) of MSM plus standard of care naproxen\n\nMSM 1000mg twice a day (6000 mgs): MSM is believed to have anti-inflammatory properties. MSM is a largely tasteless, odorless, white, crystalline solid which is water soluble. It occurs naturally in the environment and is synthesized in the human body as a byproduct of dietary DMSO.'}, {'id': 'FG001', 'title': 'Placebo Capsules Twice a Day', 'description': 'Group 2 will take by mouth three placebo capsules twice a day plus standard of care naproxen\n\nPlacebo capsules twice a day: Placebo is a capsule filled with rice flour.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '50'}, {'groupId': 'FG001', 'numSubjects': '50'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '46'}, {'groupId': 'FG001', 'numSubjects': '40'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '10'}]}]}], 'preAssignmentDetails': '86 subjects analyzed.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'BG000'}, {'value': '40', 'groupId': 'BG001'}, {'value': '86', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'MSM 1000mg Twice a Day (6000 Mgs)', 'description': 'Group 1 will take by mouth three 1000 mg capsules twice a day (6000 mgs) of MSM plus standard of care naproxen\n\nMSM 1000mg twice a day (6000 mgs): MSM is believed to have anti-inflammatory properties. MSM is a largely tasteless, odorless, white, crystalline solid which is water soluble. It occurs naturally in the environment and is synthesized in the human body as a byproduct of dietary DMSO.'}, {'id': 'BG001', 'title': 'Placebo Capsules Twice a Day', 'description': 'Group 2 will take by mouth three placebo capsules twice a day plus standard of care naproxen\n\nPlacebo capsules twice a day: Placebo is a capsule filled with rice flour.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '46', 'groupId': 'BG000'}, {'value': '40', 'groupId': 'BG001'}, {'value': '86', 'groupId': 'BG002'}]}, {'title': '>=65 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '16', 'groupId': 'BG000'}, {'value': '11', 'groupId': 'BG001'}, {'value': '27', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '30', 'groupId': 'BG000'}, {'value': '29', 'groupId': 'BG001'}, {'value': '59', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '9', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '15', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '21', 'groupId': 'BG000'}, {'value': '25', 'groupId': 'BG001'}, {'value': '46', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '8', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '10', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '46', 'groupId': 'BG000'}, {'value': '40', 'groupId': 'BG001'}, {'value': '86', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2018-04-05', 'size': 363627, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2024-03-05T08:55', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 100}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2015-02', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-04', 'completionDateStruct': {'date': '2018-06-05', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-04-03', 'studyFirstSubmitDate': '2014-10-10', 'resultsFirstSubmitDate': '2024-03-05', 'studyFirstSubmitQcDate': '2014-10-15', 'lastUpdatePostDateStruct': {'date': '2024-04-05', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2024-04-03', 'studyFirstPostDateStruct': {'date': '2014-10-20', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2024-04-05', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2018-06-05', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Pain Level', 'timeFrame': '16 weeks (Weeks 0, 4, 8, 12, and 16)', 'description': 'decrease in pain via analogue pain scale of 0-10 (with 10 being the worst pain)'}], 'secondaryOutcomes': [{'measure': 'Roland-Morris Disability Questionnaire', 'timeFrame': '16 weeks (Weeks 0, 4, 8, 12, and 16)', 'description': 'symptoms of lower back pain. 0 (no disability) to 24 (max. disability).'}, {'measure': 'Pain Impact Questionnaire-6', 'timeFrame': '16 weeks (Weeks 0, 4, 8, 12, and 16)', 'description': "6-item questionnaire measuring pain's interference with life activities. The total possible score of the PIQ-6 ranges from 40-78 points, where lower scores indicate less pain interference."}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Low Back Pain']}, 'descriptionModule': {'briefSummary': "The investigators are studying whether MSM plus standard of care naproxen improves symptoms of lower back pain compared to standard of care naproxen plus placebo. Subjects will be randomized into 1 of 2 groups. Group 1 will take by mouth 6000 milligrams (mgs) of MSM plus standard of care naproxen. Group 2 will take by mouth placebo capsules plus standard of care naproxen. Subjects will be instructed to take their study pills for 12 weeks and record on a study diary. They will then be followed up for one final visit 4 weeks later. RMDQ, PIQ-6, pain level, comprehensive metabolic panel (CMP), complete blood count (CBC) will be assessed at 4 week intervals for 12 weeks. Subjects' participation will last 16 weeks.", 'detailedDescription': 'We will recruit male and female MOFMC DoD beneficiaries between the ages of 18-65 years old with symptoms of lower back pain from any of the clinics at the MOFMC at Nellis Air Force Base. Patients taking Muscle relaxers of any type, Non-steroidal anti-inflammatory agents (NSAIDs), Tramadol, Gabapentin, Pregabalin, agree to wash out for two weeks prior to entering the study.\n\nScreening Visit:\n\n* Obtain signed Informed Consent Document and HIPAA Authorization.\n* Review inclusion/exclusion criteria.\n* Record: name, race ethnicity, race, date of birth, age, sex, height (in inches), weight (in pounds), blood pressure, email address, phone number, history of lower back surgeries, medical history, concomitant medications, and record the amount of naproxen prescribed as standard of care.\n* Subjects will have the following research-driven blood test drawn via 1 venipuncture (5-10 mls, approximately 1-2 teaspoons of blood drawn for each test) which include:\n\n * Women of childbearing potential will have a serum pregnancy test.\n * Comprehensive metabolic panel (liver function, renal function, plasma glucose tests).\n\n \\*Subjects who have had a comprehensive metabolic panel test within the one week prior to this visit will not need to have this test repeated unless they are abnormal.\n * Complete Blood Count. \\*Subjects who have had a complete blood count test within the one week prior to this visit will not need to have this test repeated unless they are abnormal.\n\nVisit 1/Day 1 (within 1 week of Screening Visit):\n\n* Subjects will be randomized by the research coordinator. We will use a minimization/dynamic determination randomization (see attached explanation of minimization/dynamic determination) technique to ensure roughly equal sample sizes. Both subjects and investigators will be blinded to the study group assignments:\n\n * Group 1 will take by mouth three 1000 mg capsules twice a day (6000 mgs) of MSM plus standard of care naproxen.\n * Group 2 will take by mouth three placebo capsules twice a day plus standard of care naproxen.\n* Subjects will be asked to complete the following questionnaires:\n\n * RMDQ\n * PIQ-6\n* Subjects will be asked "On a scale of 0-10, with 10 being the worst pain, what is your current level of pain".\n* Subjects will be given a 12 week supply of the study pills and reminded to take the pills as instructed.\n* Subjects will be given a Study Diary and will be instructed to record any missed dose of their study pills, record how much standard of care naproxen taken, and to bring the Study Diary to next visit.\n\nVisit 2/Week 4:\n\n* Record: Weight (in pounds), blood pressure, history of lower back surgeries, medical history, and concomitant medications.\n* Subjects will be asked to complete the following questionnaires:\n\n * RMDQ\n * PIQ-6\n* Subjects will be asked "On a scale of 0-10, with 10 being the worst pain, what is your current level of pain".\n* Research staff will record whether subject had any side effects to report.\n* Research staff will collect the subject\'s Study Diary, issue them a new one, and remind them to bring it with them to the next study visit.\n* Research staff will remind subjects to take the pills as instructed.\n* Subjects will have the following research-driven blood test drawn via 1 venipuncture (5-10 mls, approximately 1-2 teaspoons of blood drawn for each test) which include:\n\n * Comprehensive metabolic panel (liver function, renal function, plasma glucose tests).\n\n \\*Subjects who have had a comprehensive metabolic panel test within the one week prior to this visit will not need to have this test repeated unless they are abnormal.\n * Complete Blood Count.\n\n * Subjects who have had a complete blood count test within the one week prior to this visit will not need to have this test repeated unless they are abnormal.\n\nVisit 3/Week 8:\n\n* Record: Weight (in pounds), blood pressure, history of lower back surgeries, medical history, and concomitant medications.\n* Subjects will be asked to complete the following questionnaires:\n\n * RMDQ\n * PIQ-6\n* Subjects will be asked "On a scale of 0-10, with 10 being the worst pain, what is your current level of pain".\n* Research staff will record whether subject had any side effects to report.\n* Research staff will collect the subject\'s Study Diary, issue them a new one, and remind them to bring it with them to the next study visit.\n* Research staff will remind subjects to take the pills as instructed and to return the bottle to the research staff at the next visit.\n* Subjects will have the following research-driven blood test drawn via 1 venipuncture (5-10 mls, approximately 1-2 teaspoons of blood drawn for each test) which include:\n\n * Comprehensive metabolic panel (liver function, renal function, plasma glucose tests).\n\n \\*Subjects who have had a comprehensive metabolic panel test within the one week prior to this visit will not need to have this test repeated unless they are abnormal.\n * Complete Blood Count. \\*Subjects who have had a complete blood count test within the one week prior to this visit will not need to have this test repeated unless they are abnormal.\n\nVisit 4/Week 12 \\*SUBJECTS STOP TAKING STUDY PILLS AT THIS VISIT:\n\n* Record: Weight (in pounds), blood pressure, history of lower back surgeries, medical history, and concomitant medications.\n* Subjects will be asked to complete the following questionnaires:\n\n * RMDQ\n * PIQ-6\n* Subjects will be asked "On a scale of 0-10, with 10 being the worst pain, what is your current level of pain".\n* Research staff will record whether subject had any side effects to report.\n* Research staff will collect the subject\'s Study Diary.\n* Research staff will collect the study pills.\n* Subjects will have the following research-driven blood test drawn via 1 venipuncture (5-10 mls, approximately 1-2 teaspoons of blood drawn for each test) which include:\n\n * Comprehensive metabolic panel (liver function, renal function, plasma glucose tests).\n\n \\*Subjects who have had a comprehensive metabolic panel test within the one week prior to this visit will not need to have this test repeated unless they are abnormal.\n * Complete Blood Count. \\*Subjects who have had a complete blood count test within the one week prior to this visit will not need to have this test repeated unless they are abnormal.\n\nFinal Visit 5/Week 16:\n\n* Record: Weight (in pounds), blood pressure, history of lower back surgeries, medical history, and concomitant medications.\n* Subjects will be asked to complete the following questionnaires:\n\n * RMDQ\n * PIQ-6\n* Subjects will be asked "On a scale of 0-10, with 10 being the worst pain, what is your current level of pain".\n* Research staff will record whether subject had any side effects to report.\n* Subjects will have the following research-driven blood test drawn via 1 venipuncture (5-10 mls, approximately 1-2 teaspoons of blood drawn for each test) which include:\n\n * Comprehensive metabolic panel (liver function, renal function, plasma glucose tests).\n\n \\*Subjects who have had a comprehensive metabolic panel test within the one week prior to this visit will not need to have this test repeated unless they are abnormal.\n * Complete Blood Count. \\*Subjects who have had a complete blood count test within the one week prior to this visit will not need to have this test repeated unless they are abnormal.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'THIS STUDY IS BEING CONDUCTED AT A MILITARY INSTALLATION. YOU MUST HAVE MILITARY INSURANCE IN ORDER TO PARTICIPATE IN THIS STUDY.\n\nInclusion:\n\nDoD beneficiaries between the ages of 18-65 years old Symptoms of Low Back Pain greater than 12 weeks duration Patients with a history of lower back surgery may be included\n\nExclusion:\n\nDoD beneficiaries less than 18 years old or greater than 65 years old\n\nLower back pain caused by any of the following:\n\nInfection Tumor Osteoporosis Ankylosing spondylitis Fracture Deformity Inflammatory process Cauda equina syndrome Treated or untreated central nervous system impairment\n\nMeeting the criteria for surgery, including:\n\nprogressive motor deficit sphincter impairment from neurological cause disabling sciatic pain (in the absence of backache) lasting 6 weeks or more that is attributed to a compromised nerve root and demonstrated by magnetic resonance imaging or computed tomography Oncologic disease during the previous 5 years Unexplained weight loss, fever, or chills Diagnosed upper urinary tract infection within last 28 days Patients identified during standard of care interview to have a history of intravenous drug use.\n\nImmunocompromised host\n\nA severe comorbidity to include:\n\ndetermining overall well-being (e.g. painful disabling arthritic hip joints) Cirrhosis Ongoing dialysis Radiating symptoms to lower extremities (sciatica) History of bleeding disorders History of high blood pressure History of heart, kidney, liver or ulcer disease Allergic to analgesics or Non-steroidal anti inflammatory agents (NSAIDs) Pregnant or breastfeeding Initial pain rating of greater than 8/10 on initial intake evaluation If any of the components of the comprehensive metabolic panel are outside the Nellis clinical laboratory reference ranges, the subject will be excluded from the study\n\nIf any of these four components of the complete blood count are outside of the Nellis clinical laboratory reference ranges, the subject will be excluded from the study:\n\nWhite blood cell count Hemoglobin Hematocrit Platelets\n\nPatients taking any of the following medications are excluded from participating, unless they agree to wash out for two weeks prior to entering the study:\n\nMuscle relaxers of any type Non-steroidal anti-inflammatory agents (NSAIDs) \\* Patients taking naproxen must agree to wash out for two weeks prior to entering the study, but can begin taking it again, as prescribed, after Visit 1 where a baseline pain assessment is performed.\n\nTramadol Gabapentin Pregabalin Glucosamine Narcotic pain medications'}, 'identificationModule': {'nctId': 'NCT02268305', 'briefTitle': 'The Use of Methylsulfonylmethane (MSM) in the Treatment of Low Back Pain', 'organization': {'class': 'FED', 'fullName': "Mike O'Callaghan Military Hospital"}, 'officialTitle': 'The Use of Methylsulfonylmethane (MSM) in the Treatment of Low Back Pain.', 'orgStudyIdInfo': {'id': 'FWH20140075H'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'MSM 1000mg twice a day (6000 mgs)', 'description': 'Group 1 will take by mouth three 1000 mg capsules twice a day (6000 mgs) of MSM plus standard of care naproxen', 'interventionNames': ['Drug: MSM 1000mg twice a day (6000 mgs)']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo capsules twice a day', 'description': 'Group 2 will take by mouth three placebo capsules twice a day plus standard of care naproxen', 'interventionNames': ['Other: Placebo capsules twice a day']}], 'interventions': [{'name': 'MSM 1000mg twice a day (6000 mgs)', 'type': 'DRUG', 'otherNames': ['Methylsulfonylmethane'], 'description': 'MSM is believed to have anti-inflammatory properties. MSM is a largely tasteless, odorless, white, crystalline solid which is water soluble. It occurs naturally in the environment and is synthesized in the human body as a byproduct of dietary DMSO.', 'armGroupLabels': ['MSM 1000mg twice a day (6000 mgs)']}, {'name': 'Placebo capsules twice a day', 'type': 'OTHER', 'otherNames': ['Placebo'], 'description': 'Placebo is a capsule filled with rice flour.', 'armGroupLabels': ['Placebo capsules twice a day']}]}, 'contactsLocationsModule': {'locations': [{'zip': '89191', 'city': 'Nellis Air Force Base', 'state': 'Nevada', 'country': 'United States', 'facility': "Mike O'Callaghan Federal Medical Center", 'geoPoint': {'lat': 36.24607, 'lon': -115.05721}}], 'overallOfficials': [{'name': 'Paul Crawford, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': "Mike O'Callaghan Federal Medical Center"}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': "Mike O'Callaghan Military Hospital", 'class': 'FED'}, 'responsibleParty': {'type': 'SPONSOR'}}}}